Selective Neurocognitive Deficits Associated with Multiple Doses of Ecstasy/MDMA: A Reply to Cole

Abstract

Get full access to this article

View all access options for this article.

References

Cole J C, Sumnall H R, Wagstaff G F (2002a) What is a dose of Ecstasy? J Psychopharmacol 16: 189-191

Cole J C, Sumnall H R, Wagstaff G F (2002b) Methodological problems with Ecstasy and the SCL-90 . Psychopharmacology 97(12): 1531-1536

Fox H, Parrott A C, Turner J J D (2001) Ecstasy/MDMA related cognitive deficits: a function off dosage rather than awareness of problems . J Psychopharmacol 12: 273-281

Fox H C, McLean, A, Turner J J D, Parrott A C, Rogers R, Sahakian B J (2002) Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug free MDMA (`Ecstasy') polydrug users . Psychopharmacology 162: 203-214

Milroy C M, Clark J C, Forrest A R W (1996) Pathology of deaths associated with `Ecstasy' and `eve' . J Clin Pathol 49: 149-153

Morgan M (2002) Throwing the baby out with the bathwater? The Psychologist 12: 468-469

Parrott A C (2001a) Human psychopharmacology of Ecstasy/MDMA: a review of 15 years of empirical research . Hum Psychopharmacol 16: 557-578

Parrott A C, Milani R, Parmar R, Turner J J D (2001b) Ecstasy polydrug users and other recreational drug users in Britain and Italy: psychiatric symptoms and psychobiological problems . Psychopharmacology 159: 77-82

Parrott A C, Buchanan T, Scholey A B, Heffernan T M, Ling J, Rodgers J (2002a) Ecstasy/MDMA attributed problems reported by novice, moderate and heavy users . Hum Psychopharmacol 17(6): 309-312

10.

Parrott A C, Milani R, Turner J J D (2002b) Ecstasy and the SCL-90: a reply to Cole et al. Psychopharmacology 162: 218-223

11.

Ramsey J D, Butcher M A, Murphy M F, Lee T, Johnson A, Holt D W (2001) A new method to monitor drugs at dance venues . BMJ 232: 603-603

12.

Sherlock K, Wolff K, Hay A W M, Conner M (1999) Analysis of illicit Ecstasy tablets: implications for clinical management in the accident and emergency department . J Accident Emerg Med 16: 194-197

13.

Spruit J P (2001) Monitoring synthetic drug markets, trends and public health . Subst Use Misuse 36: 23-47

14.

Topp L, Hando J, Dillon P, Roche A, Solowij N (1999) Ecstasy use in Australia: patterns of use and associated harm . Drug Alcohol Depend 55: 105-115

15.

World Health Organization (1996) Amphetamine like stimulants . Report from the WHO meeting on amphetamines, MDMA and other psychostimulants, November 1996, Geneva, Switzerland